Pregnenolone methyl ether

Drug Profile

Pregnenolone methyl ether

Alternative Names: 3-methoxy-pregnenolone - Mapreg; MAP-4343

Latest Information Update: 22 Apr 2016

Price : *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Mapreg
  • Class Steroids
  • Mechanism of Action Microtubule-associated protein stimulants; Tubulin polymerisation promoters
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Spinal cord injuries
  • New Molecular Entity Yes

Highest Development Phases

  • Phase I Brain injuries; Spinal cord injuries
  • Preclinical Depressive disorders

Most Recent Events

  • 22 Apr 2016 Pregnenolone methyl ether is still in phase I trials for Spinal cord injuries and in preclinical trials for Depressive disorders in France
  • 22 Apr 2016 Chemical structure information added
  • 22 Apr 2016 Phase-I clinical trials in Brain injuries in France (Parenteral)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top